Contrast-Enhanced Ultrasonography (CEUS) Predicts the Effectiveness of Anti-Angiogenic Therapies in Patients with Liver Metastases from Neuroendocrine Tumors

#725

Introduction: Liver metastases (LM) from neuroendocrine tumors (NETs) exhibit a typical hypervascular pattern in the arterial phase on CEUS, allowing for a differential diagnosis between NET and non-NET LM. Medical therapy includes agents acting on angiogenesis and vascularization which may result in a change in CEUS findings.

Aim(s): To investigate the role of CEUS to predict the effectiveness of anti-angiogenic therapies in patients with LMs from NTs.

Materials and methods: Thirty pts with multiple LMs from NETs were enrolled. All pts underwent therapy with somatostatin analogues which was combined with sunitinib in three and everolimus in two of them. CEUS was performed at baseline and one, three, six and 12 months after anti-angiogenic treatment. CEUS was compared with contrast-enhanced multidetector-row CT performed at baseline and 6 - 12 months after treatment.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Di Sarno A

Authors: Di Sarno A, Del Prete M, Marotta V, De Stefano G, Marciello F,

Keywords: neuroendocrine tumor, liver metastases, CEUS, contrast enhancement, predictive factor of response,

To read the full abstract, please log into your ENETS Member account.